Powerheart G5
ZOLL MEDICAL CORPORATION · Decision date Apr 28, 2026
What did the FDA approve?
FDA records P160033/S011 as a supplement to PMA P160033, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 28, 2026.
FDA approval order statement
approval for update to the software resulting in version v4.31. This version includes cybersecurity enhancements, removal of configurability of the rescue protocol, and disabling of the manufacturing/debug serial port.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 28, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P160033/S011
- Regulatory pathway
- PMA supplement
- Applicant
- ZOLL MEDICAL CORPORATION
- Product code
- MKJ
- Decision code
- APPR
- Decision date
- Apr 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated external defibrillators (non-wearable).
- Applicant
- ZOLL MEDICAL CORPORATION
- Product code
- MKJ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160033/S011 received
Application receipt date recorded by FDA.
P160033/S011 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P160033. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MKJ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIFEPAK 35 monitor/defibrillatorP160026/S076 | Physio-Control, Inc. | PMA supplement | Oct 29, 2026 | FDA |
AED 3 Defibrillator with Uni-PadzP160015/S029 | ZOLL MEDICAL CORPORATION | PMA supplement | Oct 16, 2026 | FDA |
ZOLL R Series Monitor/DefibrillatorP160022/S056 | ZOLL MEDICAL CORPORATION | PMA supplement | Oct 16, 2026 | FDA |
| ZOLL MEDICAL CORPORATION | PMA supplement | Oct 2, 2026 | FDA | |
| Physio-Control, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
ZOLL MEDICAL CORPORATION
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 269 Mill Rd., Chelsmford, MA, 01824
Sources and methodology
- Original FDA record: P160033/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

